LONDON, August 17, 2016 /PRNewswire/ --
Clinical Chemistry, Immunochemistry, Haematology, Microbiology, Genetic Testing, Point of Care Diagnostics, Blood Glucose Testing, Infectious Diseases Testing, Rapid Cardiac Market Testing, Cholesterol Testing, Pregnancy Testing
The In Vitro Diagnostics World Market 2016-2026: Clinical Chemistry, Immunochemistry, Haematology, Microbiology, Genetic Testing, Point of Care Diagnostics, Blood Glucose Testing, Infectious Diseases Testing, Rapid Cardiac Market Testing, Cholesterol Testing, Pregnancy Testing report assesses the global market for IVDs. The market is first split and forecasted by submarket.
Six main submarkets are covered, these are the:
• Point-of-care diagnostics (PoC)
• Clinical chemistry
• Immunochemistry
• Haematology
• Microbiology
• Genetic testing
The leading submarket in the IVD industry at present and throughout the next decade will be point-of-care diagnostics. This submarket is further subdivided into more specific tests. Blood glucose testing accounted for over half of the revenue PoC testing made in 2015 due to the rise in prevalence of diabetes.
What are the prospects in the leading regions and countries?
In our study you will find individual revenue forecasts to 2026 for the leading regional and national markets:
• US
• Japan
• Germany
• France
• UK
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
• Spain
• Italy
• China
• India
• Brazil
• Russia
• Rest of the World
The US, Japan and China were the 1st 2nd and 3rd leading national markets in 2015 and each will retain its place over the next 10 years. India will be the fastest growing national market from 2015-2026 with China close behind.
Our new report discusses issues and events affecting the IVD market. You will find discussions, including qualitative analyses on:
• The global IVD market
• The IVD market divided by submarket including; point-of-care, clinical chemistry, haematology, immunochemistry, microbiology and genetic testing
• The challenges facing the market, such as the US excise tax on medical devices
• The latest merger & acquisition activity amongst industry leaders
• 11 different national markets including the 'EU5' and 'BRIC' nations
Visiongain predicts that the demand for IVDs will increase in line with the rise in both incidence and prevalence of chronic and infectious diseases. Health professionals will recognise that if these diseases can be diagnosed at the earliest stage possible, then damage to the individual can be minimised in addition to a reduction of later costs to healthcare systems. IVDs will be able to stem the economic and clinical costs of chronic and infectious disease.
The drive to provide patients with diagnostic testing options that are more accurate, easy-to-use and convenient will sustain growth in the IVD market during the forecast period of this report.
Our 166 page report provides 38 tables and 72 figures covering 6 different IVD submarkets. 11 individual national markets are covered in addition to coverage of the leading companies in the industry. Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, a primary interview, industry trends, opportunities, and revenue predictions. The increasing prevalence of both chronic and infectious diseases will ensure that there is a great demand for use and innovation of IVDs over the next decade and beyond.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
To request a report overview of this report please emails Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100
Or click on https://www.visiongain.com/Report/1711/In-Vitro-Diagnostics-World-Market-2016-2026
Companies and Organisations Mentioned
3M
Abbott Laboratories
AbbVie
Adaltis
AdnaGen AG
Affymetrix
Agendia
Agilent
Akonni Biosystems
Alere
Amgen
Arkay
AssuraGen
Astute Medical
Atlas Genetics
Bayer
Beckman Coulter
Binding Site
Biohit HealthCare
bioMérieux
Bio-Rad
BioSystems
Bristol Myers-Squibb
CardioGenics
Celerus Diagnostics
Center for Devices and Radiological Health (CDRH) [part of US FDA]
Cepheid
Claros Diagnostics
Cognex
Compendia Bioscience
Corgenix
Crescendo Bioscience
Dako
Danaher
Daxor Corporation
Devicor Medical Products
DiaGenic
DiaSorin
Diaxonhit
Diazyme Laboratories
European Commission (EC)
European Diagnostic Manufacturers Association (EDMA)
European Medicines Agency (EMA)
Expression Diagnostics
Foundation for Innovative and New Diagnostics (FIND)
Fujirebio Diagnostics Inc.
Gene Chip Research Centre, Tianjin, China
Genentech
GenMark Diagnostics
Genomic Health
Gen-Probe
Gifu University
Glycominds
Hai Kang Life Corporation
Haplogen Genomics GmbH
HemoCue
Hoffman-La Roche
Hologic
Human Genetics Commission
Immucell
Immucor
Innogenetics
Innova Biotechnology Co.
Instrumentation Laboratory
Ipsogen
Janssen Biotech
Janssen Pharmaceuticals
Japanese Ministry of Health and Welfare
Johnson & Johnson
Kreatech Diagnostics
Lab-21
LabIndia
Launch Diagnostics
Leica Microsystems
Life Technologies
LifeScan
Luminex
Med BioGene
Melanoma Diagnostics
Meridian Bioscience
Milagen
Mindray
Miraca Life Sciences
Myriad Genetics
Nanosphere
National Institute of Clinical Excellence (UK NICE)
Novartis
Onconome
Orion Genomics
Ortho Clinical Diagnostics
PathWorks Diagnostics
PerkinElmer
Pharmaceutical and Medical Devices Agency, Japan (PMDA)
Phillips
Polymedco
Qiagen
Quest Diagnostics
Radiometer Medical
Randox Laboratories
Response Biomedical
Roche
Rules-Based Medicine
Saladax Biomedical
Sanofi
SDIX
Sekisui Diagnostics
Sera Prognostics
SeraCare Life Sciences
Siemens
Span Diagnostics
St Jude Medical
Stago
STARLIMS Technologies
SterilMed
Suzhou Ribo Life Sciences
Synthes
Sysmex
Target Discovery
Targeted Diagnostics & Therapeutics
Tethys Bioscience
The Carlyle Group
Tocagen
Tosoh Bioscience
Transasia Bio Medicals
Trinity Biotech
United Nations (UN)
UroSens
US Food and Drug Administration (FDA)
VentriPoint
Verax Biomedical
Vermillion
ViiV Healthcare
World Health Organization (WHO)
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Share this article